RecruitingNot Applicable

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

United States350 participantsStarted 2026-01-17

Plain-language summary

This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible.
✓. Manage CSU patients within their practice.
✓. Enrolled in the research network or are referred HCPs who agree to participate.

Exclusion criteria

✕. ≥ 18 years of age.
✕. Diagnosed with CSU by an HCP.
✕. Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
✕. Have access to an electronic device with internet capabilities.
✕. Able to read and understand English.
✕0. Willing and able to provide consent for study participation.
✕. Unable to procure remibrutinib or dupilumab (through samples, commercially or patient assistance program).
✕. Exposure to oral corticosteroid treatment in 14 days prior to consent.

What they're measuring

Change From Baseline in Urticaria Control Test - 7 Day Recall (UCT-7) Score at Week 4 in Patients Initiating Remibrutinib

Timeframe: Baseline and Week 4

Trial details

NCT IDNCT07408219

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-03-31

Contact for this trial

Novartis Pharmaceuticals

+41613241111 novartis.email@novartis.com

View on ClinicalTrials.gov More Chronic Spontaneous Urticaria trials